Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies reported a record-setting performance for fiscal year 2021, with fourth-quarter revenue of $1.66 billion, reflecting a 12% growth. The GAAP net income reached $442 million, resulting in an EPS of $1.45, a significant 104% increase year-over-year. For fiscal 2021, total revenue was $6.32 billion, an 18% increase, and full-year net income was $1.21 billion, with an EPS of $3.94.
Looking ahead, Agilent expects 2022 revenue between $6.65 billion and $6.73 billion, with first-quarter revenue guidance of $1.64 billion to $1.66 billion
Agilent Technologies (NYSE: A) has appointed Dr. Otis W. Brawley, a leading authority in oncology, to its board of directors, effective November 17, 2021. Dr. Brawley, who is affiliated with Johns Hopkins University, brings extensive expertise in cancer screening and prevention, focusing on reducing disparities in cancer care. His prior roles include chief medical and scientific officer at the American Cancer Society. Agilent's CEO, Mike McMullen, emphasized that Dr. Brawley's insights will enhance Agilent's cancer diagnostics focus, positioning the company as a leader in this area.
Agilent Technologies (NYSE: A) has announced an 8% increase in its quarterly dividend, raising it to 21 cents per share. This dividend will be payable on January 26, 2022, to shareholders on record as of January 4, 2022. The company reported $5.34 billion in revenue for fiscal year 2020 and employs approximately 16,400 people globally. Future dividends will be subject to board approval.
Agilent Technologies (NYSE: A) announced the appointment of John Palma as vice president of Medical Affairs. With over 26 years in diagnostics and research, Palma will lead the companywide Global Medical Affairs organization, focusing on liquid biopsy development. His prior experience includes senior roles at Roche, enhancing Agilent's position in cancer diagnostics and precision oncology. This strategic move follows Agilent's acquisition of Resolution Bioscience, demonstrating a commitment to advancing capabilities in next-generation sequencing.
Agilent Technologies (NYSE: A) has launched the new 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. These innovations support biopharma research, enhancing the analysis of proteins and peptides, crucial for developing new therapeutics. They address regulatory compliance and improve data integrity. Agilent's solutions are showcased at the American Society for Mass Spectrometry Conference from October 31 to November 4, 2021, in Philadelphia.
Agilent Technologies (NYSE: A) announced that its PD-L1 IHC 22C3 pharmDx assay is now approved for identifying triple-negative breast cancer (TNBC) patients eligible for treatment with KEYTRUDA® in Europe. PD-L1 expression is crucial for anti-PD-1 therapy responses. The assay, already used in four other cancer types, enhances pathologists' ability to identify suitable patients. With over 530,000 new breast cancer cases in Europe in 2020, this approval significantly expands Agilent's diagnostic capabilities, reinforcing its leadership in companion diagnostics.
Agilent Technologies Inc. (NYSE: A) will announce its fourth-quarter fiscal year 2021 financial results post market close on November 22, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific Time on the same day. In fiscal year 2020, the company reported a revenue of $5.34 billion and employs 16,400 people globally. The webcast will be available on their website for 90 days after the event.
Summary not available.
Agilent Technologies (NYSE: A) has achieved the highest sponsorship level with My Green Lab as the first to do so. This partnership enhances Agilent's commitment to sustainability in scientific research, emphasizing green purchasing practices. Since its inception in 2013, My Green Lab focuses on improving environmental responsibility in labs. Agilent has received My Green Lab's ACT labels for major product lines and sponsors the certification program recognized in the UNFCCC's 2030 Breakthroughs. Agilent is consistently ranked among the world's most sustainable corporations.
Agilent Technologies Inc. (NYSE: A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx, intended to assist in first-line treatment decisions for adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric and esophageal cancers are significant global health issues, with over 1.6 million cases reported in 2020. The PD-L1 IHC 28-8 pharmDx enhances treatment confidence when used with OPDIVO® (nivolumab), demonstrating superior survival rates compared to chemotherapy alone.